Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2018

22.01.2018 | Brief Report

Management and outcomes of women diagnosed with primary breast lymphoma: a multi-institution experience

verfasst von: Nafisha Lalani, Karen M. Winkfield, Daniel E. Soto, Beow Y. Yeap, Andrea K. Ng, Peter M. Mauch, Rachel B. Jimenez

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Primary breast lymphoma (PBL) comprises < 1% of breast malignancies, leading to a paucity of data to guide management. We evaluated PBL recurrence patterns across two academic hospitals in the era of modern systemic-therapy and radiotherapy.

Methods

Patients diagnosed with PBL between October 1994 and June 2016 were identified. Demographic/clinical variables were assessed via primary chart review. Local control (LC) was estimated using the cumulative incidence function and overall survival (OS) using the Kaplan–Meier method.

Results

Thirty-five patients were identified. Median follow-up 5.8 years (range 0.3–17.8 years). Median age at diagnosis 66 years (range 35–86 years). Indolent versus aggressive lymphoma represented 57% (n = 20) and 43% (n = 15) of the cohort, respectively. All patients with aggressive lymphoma received systemic therapy. Thirty patients (86%) received radiotherapy (RT). Breast-only RT was used in 57% (n = 20); 23% (n = 7) received regional nodal irradiation (RNI), and 6% (n = 2) received limited-field RT. Local recurrences were observed in 3% (n = 1), contralateral breast 9% (n = 3), CNS 6% (n = 2), distant non-CNS 30% (n = 10), both local and distant 3% (n = 1). There were no regional nodal recurrences. The 6-year LC rate was 95% for indolent and 81% for aggressive subtypes. The 6-year OS rate was 87% for indolent and 70% for aggressive subtypes.

Conclusions

The majority of patients in this PBL cohort received breast-only RT with no nodal relapses, suggesting that prophylactic RNI may be unnecessary. Given the prevalence of contralateral breast involvement at diagnosis and at recurrence, vigilant surveillance of bilateral breasts may be warranted. The role of CNS prophylaxis requires further investigation.
Literatur
1.
Zurück zum Zitat Strobbe L, Peterse H, Van Tinteren H et al (1998) Angiosarcoma of the breast after conservation therapy for invasive cancer, the incidence and outcome. An unforseen sequela. Breast Cancer Res Treat 47(2):101CrossRefPubMed Strobbe L, Peterse H, Van Tinteren H et al (1998) Angiosarcoma of the breast after conservation therapy for invasive cancer, the incidence and outcome. An unforseen sequela. Breast Cancer Res Treat 47(2):101CrossRefPubMed
4.
Zurück zum Zitat Yahalom J, Illidge T, Specht L (2015) Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys 92(1):11–31CrossRefPubMed Yahalom J, Illidge T, Specht L (2015) Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys 92(1):11–31CrossRefPubMed
5.
Zurück zum Zitat Ryan G, Roos D, Seymour J (2006) Primary non-Hodgkin’s lymphoma of the breast: retrospective analysis of prognosis and patterns of failure in two Australian centers. Clin Lymphoma Myeloma 6(4):337–341CrossRefPubMed Ryan G, Roos D, Seymour J (2006) Primary non-Hodgkin’s lymphoma of the breast: retrospective analysis of prognosis and patterns of failure in two Australian centers. Clin Lymphoma Myeloma 6(4):337–341CrossRefPubMed
6.
Zurück zum Zitat Ryan G, Martinelli G, Kuper-Hommel M et al (2008) Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group. Ann Oncol 19(2):233–241CrossRefPubMed Ryan G, Martinelli G, Kuper-Hommel M et al (2008) Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group. Ann Oncol 19(2):233–241CrossRefPubMed
7.
Zurück zum Zitat Topalovski M, Crisan D, Mattson J (1999) Lymphoma of the breast. A clinicopathologic study of primary and secondary cases. Arch Pathol Lab Med 123(12):1208PubMed Topalovski M, Crisan D, Mattson J (1999) Lymphoma of the breast. A clinicopathologic study of primary and secondary cases. Arch Pathol Lab Med 123(12):1208PubMed
9.
Zurück zum Zitat Wong W, Schild S, Halyard M (2002) Primary non-Hodgkin lymphoma of the Breast: The Mayo Clinic Experience. J Surg Oncol 80:19–25CrossRefPubMed Wong W, Schild S, Halyard M (2002) Primary non-Hodgkin lymphoma of the Breast: The Mayo Clinic Experience. J Surg Oncol 80:19–25CrossRefPubMed
Metadaten
Titel
Management and outcomes of women diagnosed with primary breast lymphoma: a multi-institution experience
verfasst von
Nafisha Lalani
Karen M. Winkfield
Daniel E. Soto
Beow Y. Yeap
Andrea K. Ng
Peter M. Mauch
Rachel B. Jimenez
Publikationsdatum
22.01.2018
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2018
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-018-4671-8

Weitere Artikel der Ausgabe 1/2018

Breast Cancer Research and Treatment 1/2018 Zur Ausgabe

Rebuttal Letter

Reply to K. Altundag

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.